Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2011; 105(04): 571-573
DOI: 10.1160/TH11-01-0053
DOI: 10.1160/TH11-01-0053
Invited Editorial Focus
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery
Authors
Further Information
Publication History
Received:
31 January 2011
Accepted:
04 February 2011
Publication Date:
28 November 2017 (online)
Editorial Focus on: Eriksson et al. Thromb Haemost 2011; 105: 721-729.
-
References
- 1 Agnelli G, Eriksson BI, Cohen AT. et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009; 123: 488-497.
- 2 Huisman MV, Quinlan DJ, Dahl OE. et al. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010; 3: 652-660.
- 3 Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism – systematic review and adjusted indirect comparison. J Clin Pharm Ther 2011; 36: 111-124.
- 4 Turpie AGG, Bauer KA, Eriksson BI. et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-1840.
- 5 Turpie AG, Lassen MR, Eriksson BI. et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2010; 105: 444-453.
- 6 Wolowacs SE, Roskell NS, Plumb JM. et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 77-85.
- 7 Lassen MR, Raskob GE, Gallus A. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
- 8 Lassen MR, Raskob GE, Gallus A. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
- 9 Lassen MR, Gallus A, Raskob GE. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498.
- 10 Eriksson BI, Dahl OE, Huo MH. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721-729.
- 11 Lassen MR, Bauer KA, Eriksson BI. et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet 2002; 359: 1715-1720.
- 12 Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
- 13 Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
- 14 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.